No Data
No Data
Beam Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.
Beam Therapeutics Analyst Ratings
Promising Early Data and Innovative Approaches Lead to Buy Rating for Beam Therapeutics
Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains
BofA Securities Initiates Beam Therapeutics(BEAM.US) With Hold Rating, Announces Target Price $42
Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday